Flowcytometry Immunophenotyping: Role in Acute Leukemia and Detection of Aberrant Expressions in the Indian Population

Namrata Singh *

Department of Hematology, Metropolis Healthcare Ltd, Mumbai, India.

Sanjay Gohil *

Department of Hematology, Metropolis Healthcare Ltd, Mumbai, India.

Jyothi Mathias *

Department of Hematology, Metropolis Healthcare Ltd, Mumbai, India.

Reshma Haryan *

Department of Hematology, Metropolis Healthcare Ltd, Mumbai, India.

Shamika Dhole *

Department of Hematology, Metropolis Healthcare Ltd, Mumbai, India.

Shibani Ramchandran *

Metropolis Healthcare Ltd, Mumbai, India.

Raj Jatale *

Metropolis Healthcare Ltd, Mumbai, India.

Kirti Chadha *

Metropolis Healthcare Ltd, Mumbai, India.

*Author to whom correspondence should be addressed.


Abstract

Aim: To study the distribution of Acute Leukemia cases, and the expression of commonly used Cluster of Differentiation (CD markers) in sub-classification of Acute Leukemia and aberrant expression of these markers.

Methods:  The retrospective study was conducted at a Global Reference Lab in Mumbai from January 2017 to December 2021 on 1538 Acute Leukemia cases diagnosed based on 20% & more blasts on morphology and Flowcytometry immunophenotyping. 

Results: Out of 1538 Acute Leukemia(AL) cases, Acute Myeloid Leukemia (AML) was found to be more common (59.49%) than Acute Lymphoid Leukemia (ALL) (39.27%). Age distribution showed that ALL was more common in paediatric age group whereas AML was seen more common in adults and old age. In further analysis of ALL, B-ALL was found higher as compared to T-ALL. CD33 (92.74%), CD19 (100%) and CD7 (97.79%) were most sensitive markers for AML, B-cell and T-cell respectively. CD7, CD33 and CD13 were most common expressed aberrant markers found in them respectively.

Conclusion: Flowcytometry immunophenotyping is indispensable, fastest and very precise tool in defining lineage of Acute Leukemia and identification of Mixed Phenotypic Acute Leukemia (MPAL) and Undifferentiated Leukemia. Aberrant expression of markers guides for further cytogenetic and molecular studies to great extent and identification of blasts during assessment of minimal residual disease.

Keywords: Acute leukemia (AL), Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Flowcytometry, aberrant markers, cluster of differentiation (CD), Mixed Phenotypic Acute Leukemia (MPAL), Minimal Residual Disease (MRD)


How to Cite

Singh , Namrata, Sanjay Gohil, Jyothi Mathias, Reshma Haryan, Shamika Dhole, Shibani Ramchandran, Raj Jatale, and Kirti Chadha. 2024. “Flowcytometry Immunophenotyping: Role in Acute Leukemia and Detection of Aberrant Expressions in the Indian Population”. Asian Hematology Research Journal 7 (2):83-95. https://journalahrj.com/index.php/AHRJ/article/view/171.

Downloads

Download data is not yet available.

References

Ouyang G, Xu Z, Jiang D, Zhu H, Wang Y, Wu W, Sun Y, Sheng L, Xu K, Lou Y, Mu Q, Zhang Y, Wu N, Cheng J, Duan S. Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia. The Journal of International Medical Research. 2019;47(4):1483–1492. Available:https://doi.org/10.1177/0300060518819637

Li W. Flow cytometry in the diagnosis of hematological neoplasms and other cancers. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham; 2023. Available:https://doi.org/10.1007/978-3-030-80962-1_145-1

Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Archives of Pathology and Laboratory Medicine. 2011;135(1):44–54. Available:https://doi.org/10.5858/2010-0387-RAR.1

Gupta M, Monga L, Mehrotra D, Chhabra S, Singhal S, Sen R. --Immunophenotypic Aberrancies in Acute Leukemia: A Tertiary Care Centre Experience. Oman Medical Journal. 2021;36(1):e218. Available:https://doi.org/10.5001/omj.2021.03

WHO Classification of Haematolymphoid Tumours, 5th edition; 2022.

Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941–3967. Available:https://doi.org/10.1182/blood-2007-11-120535

Adan A, Alizada G, Kiraz Y, et al. Flow cytometry: Basic principles and applications. Crit Rev Biotechnol. 2017; 37(2):163–176. Available:https://doi.org/10.3109/07388551.2015.1128876. Epub 2016 Jan 14. PMID: 26767547

Gajendra S. Flowcytometry in Acute Leukemia. Clin Oncol. 2016;1:1166.

Raza H, Fatima M, Noor T, et al. The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukemia Patients. Cureus. 2022;14(2):e22309. DOI: 10.7759/cureus.22309

Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. American Journal of Clinical Pathology. 2009;132(6):940–949. Available:https://doi.org/10.1309/AJCP8G5RMTWUEMUU

Gujral S, Badrinath Y, Kumar A, Subramanian PG, Raje G, Jain H, Pais A, Kadam PSA, Banavali SD, Arora B, Kumar P, Hari Menon VG, Kurkure PA, Parikh PM, Mahadik S, Chogule AB, Shinde SC, Nair CN. Immunophenotypic profile of acute leukemia: Critical analysis and insights gained at a tertiary care center in India. Cytometry Part B. 2009;76B:199–205.

De-Morgan A, Meggendorfer M, Haferlach C, et al. Male predominance in AML is associated with specific preleukemic mutations. Leukemia. 2021;35:867–870 Available:https://doi.org/10.1038/s41375-020-0935-5

Ozga M, Nicolet D, Mrózek K, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024;38: 45–57. Available:https://doi.org/10.1038/s41375-023-02068-8

Möricke Anja, Ratei, Richard, Ludwig, Wolf-Dieter, Harbott, Jochen, Borkhardt, Arndt, Viehmann, Susanne, Zimmermann, Martin, Gadner, Helmut, Riehm, Hansjörg, Schrappe, Martin. Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95. Blood. 2004;104:1957-1957. DOI: 10.1182/blood.V104.11.1957.1957.

Salem DA, Abd El-Aziz SM. Flowcytometric immunophenotypic profile of acute leukemia: mansoura experience. Indian J Hematol Blood Transfus. 2012; 28(2):89-96.

DOI: 10.1007/s12288-011-0110-2. Epub 2011 Sep 21. PMID: 23730015; PMCID: PMC3332273.

Sarma A, Hazarika M, Das D, Kumar Rai A, Sharma JD, Bhuyan C, Kataki AC. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenotyping by multiparameter flowcytometry. Cancer biomarkers: Section A of Disease Markers. 2015;15(4):501–505 Available:https://doi.org/10.3233/CBM-150482

Saghir A. Jafri, Abdul Mannan, Aftab Nadeem, Asif Jamal. Frequency of aberrant expression of cd markers in cases of acute Leukemia. Med J Islamic World Acad Sci. 2010;18(2):55-60.

Kumar J, Khan AA, Saraf A, Bhargava M. Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia. Indian Journal of Hematology and Blood Transfusion: An Official Journal of Indian Society of Hematology and Blood Transfusion. 2014;30(1):16-18. DOI: 10.1007/s12288-012-0216-1. PMID: 24554814; PMCID: PMC3921324.

Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer Journal. 2017;7(6):e577. Available:https://doi.org/10.1038/bcj.2017.53

Venugopalan, Radhika K, Singh, Neha, Anthony, Michael, Kunnumbrath, Arathi, Gupta, Arvind K, Nath, Uttam K, Chowdhury, Nilotpal, Chandra, Harish. Leukemia- associated aberrant immunophenotype: A flow cytometry-based experience of 110 cases from a tertiary care center in Northern India. Journal of Cancer Research and Therapeutics. 2023;19(5):1335-1339. DOI: 10.4103/jcrt.jcrt_809_21

Abdul Hamid, Gamal, Akrabi, Mayson. Aberrant Antigen Expression in Patients with Acute Leukemia in National Oncology Center Aden; 2019.

Sharma M, Varma N, Singh Sachdeva MU, Bose PL, Varma S. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation. Journal of Cancer Research and Therapeutics. 2020;16(1):105-109.

Mazher N, Malik N, Imran AK, Chughtai O. (2013). Aberrant expression of cd markers in acute Leukemia. Ann Pak Inst Med Sci. 2013;9(2):99-102.

Suggs JZ, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Experimental and Molecular Pathology. 2007;83(3):471–473 Available:https://doi.org/10.1016/j.yexmp.2007.08.012

Asif Rashed, Shirin Tarafder, Humayun Sattar, Sadia Hossain. Expression of aberrant antigens in adult acute leukemia: A study in Bangladesh. International Journal of Cancer Research. 2020;16:28-34.

Gupta DG, Varma N, Naseem S, Sachdeva MUS, Bose P, Binota J, Kumar A, Gupta M, Rana P, Sonam P, Malhotra P, Trehan A, Khadwal A, Varma S. Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients. Turk J Haematol. 2022;39(1):1-12.

DOI: 10.4274/tjh.galenos.2021.2021.0326. Epub 2021 Oct 7. PMID: 34617433; PMCID: PMC8886275.

Supriyadi E, Veerman AJ, Sutaryo, Purwanto I, Vd Ven PM, Cloos J. Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol. Journal of Oncology. 2012;135186. Available:https://doi.org/10.1155/2012/135186

Shahni A, Saud M, Siddiqui S, Mukry SN. Expression of aberrant antigens in hematological malignancies: A single center experience. Pak J Med Sci. 2018; 34:457–62.